Research Article
Effect of Exogenous Melatonin Administration in Critically Ill Patients on Delirium and Sleep: A Randomized Controlled Trial
Table 4
Sleep analysis in study groups.
| | Group A | Group B | P | N = 21 | N = 12 | Melatonin | Placebo | Median (IQR) | Median (IQR) |
| Hrs studied from 7pm, baseline | 10 (10–10) | 10 (10–10) | 0.80 | Hrs studied from 7pm, drug | 10 (10–10) | 10 (10–10) | 0.57 | Arousal index | Baseline | 8.95 (6.6–20.3) | 7.6 (6.6–20.3) | 0.80 | Posttreatment | 12.9 (8.4–24.4) | 15.7 (1.8–66) | 0.81 | Sleep stages | N = 14 | N = 8 | | Stage 1 (%) | Baseline | 0.26 (0.00–1.00) | 0 (0.0–1.7) | 0.37 | Posttreatment | 2.17 (0.75–3.25) | 0.25 (0.0–2.03) | 0.10 | Change from baseline to posttreatment | 0.89 (−0.33–2.42) | 0.17 (−0.04–0.60) | 0.39 | Stage 2 (%) | Baseline | 24.67 (6.93–40.08) | 2.92 (0.17–15.75) | 0.02 | Posttreatment | 21.17 (15.57–43.15) | 16.30 (6.35–31.25) | 0.13 | Change from baseline to posttreatment | −3.49 (−9.27–15.83) | 9.35 (1.56–27.18) | 0.25 | Stage 3 (%) | Baseline | 11.67 (5.23–54.81) | 7.00 (0.50–83.33) | 0.94 | Posttreatment | 16.50 (1.92–29.33) | 54.58 (11.05–59.52) | 0.02 | Change from baseline to posttreatment | 17.54 (1.92–29.33) | 46.03 (10.3–58.17) | 0.08 | REM (%) | Baseline | 0 (0–0.08) | 0 (0–0) | 0.32 | Posttreatment | 1.05 (0–4.42) | 0 (0–0) | 0.05 | Change from baseline to posttreatment | 0.13 (0–1.5) | 0 (0–0) | 0.35 | Awake (%) | Baseline | 32.50 (13.07–58.5) | 69.08 (13.86–96) | 0.62 | Posttreatment | 45.69 (34.02–70.67) | 21.29 (3.50–61.63) | 0.22 | Change baseline to posttreatment | 8.34 (−13.17–15.42) | −11.56 (−47.10–3.93) | 0.22 |
|
|